GlobeNewsWire
25 Jun 2026, 02:33 UTC · 21w ago
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Impact · against what's priced in
Taysha Gene Therapies (TSHA) is facing immediate share dilution from a $200 million public offering, though the cash infusion significantly extends its operational runway. While the capital is critical for its clinical-stage development, the offering price and the scale of dilution act as a near-term drag on the stock price.
- TSHA−0.10
No priced-in read yet





